期刊导航

论文摘要

伊莎妥昔单抗治疗多发性骨髓瘤的研究进展

Research progress on treatment of multiple myeloma with isatuximab-irfc

作者:

Author:

收稿日期:2020-07-14          年卷(期)页码:2020,43(06):538-542

期刊名称:国际输血及血液学杂志

Journal Name:International Journal of Blood Transfusion and Hematology

关键字:多发性骨髓瘤,抗体,单克隆,伊莎妥昔单抗,药物疗法,抗原,CD38

Key words:Multiple myeloma|Antibodies, monoclonal|Isatuximab|Drug therapy|Antigens, CD38

基金项目:

中文摘要

多发性骨髓瘤(MM)是一种以浆细胞恶性增殖,并通过分泌大量功能缺陷的免疫球蛋白(Ig)及其片段,同时抑制正常浆细胞增殖及Ig分泌,进而造成相关组织或器官损伤的血液系统恶性疾病。伊莎妥昔单抗是一种人工合成,可与IgG1嵌合的新型单克隆抗体药物,其与MM细胞表面的CD38受体结合后,进而通过多种机制诱导MM细胞凋亡。目前,伊莎妥昔单抗主要用于复发/难治性MM(RRMM)的治疗。笔者从伊莎妥昔单抗治疗MM的作用机制、临床疗效及药物不良反应等方面的研究新进展进行阐述。

英文摘要

Multiple myeloma (MM) is a hematological malignancies with plasma cell malignant proliferation, which inhibits the proliferation of normal plasma cells and the secretion of immunoglobulin(Ig) by secreting a large number of Ig and its fragments with defective functions, thus causing injury to relevant organs or tissues. Isatuximab-irfc (sarclisa) is a novel synthetic monoclonal antibody that chimeric with IgG1, which can bind to the CD38 receptor on MM cells and induce MM cell apoptosis through various mechanisms.Isetuximab-irfc is currently used for the treatment of relapsed/refractory MM (RRMM). This review elaborates on the advances in the mechanisms, clinical efficacy and adverse reactions of isatuximab-irfc in the treatment of MM.

上一条:异基因造血干细胞移植治疗骨髓增生异常综合征的新进展

关闭

Copyright © 2020四川大学期刊社 版权所有.

地址:成都市一环路南一段24号

邮编:610065